Ignite Creation Date:
2025-12-26 @ 11:11 AM
Ignite Modification Date:
2025-12-31 @ 5:43 PM
Study NCT ID:
NCT00037128
Status:
UNKNOWN
Last Update Posted:
2005-06-24
First Post:
2002-05-16
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study of GL701 in Men With Systemic Lupus Erythematosus
Sponsor:
Genelabs Technologies
Organization:
Study Overview
Official Title:
None
Status:
UNKNOWN
Status Verified Date:
2004-05
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Lupus flares and other symptoms associated with systemic lupus erythematosus (SLE) may be caused by a deficiency of dehydroepiandrosterone (DHEA). GL701 is an investigational new drug meant to enhance DHEA levels. This study is designed to evaluate both the safety and efficacy of GL701 in male lupus patients.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: